Stock KBLM 180 LIFE SCIENCES CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Company 180 Life Sciences Corp.

Equities

KBLM

US68236V3024

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:30:00 26/04/2024 BST 		5-day change 1st Jan Change
1.8 USD +1.76% Intraday chart for 180 Life Sciences Corp. -1.10% -55.63%
03-25 180 Life Sciences Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
03-11 180 Life Sciences Corp. Announces Board Changes CI

Business Summary

180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis. The Company is primary focused on program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor). The Company has three product development platforms: Anti-TNF platform, SCAs platform and a7nAChR platform. Anti-TNF platform is focused on fibrosis and anti-tumor necrosis factor (anti-TNF). SCAs platform is focused on drugs which are synthetic cannabidiol (CBD) or cannabigerol (CBG) analogues (SCAs). a7nAChR platform is focused on alpha 7 nicotinic acetylcholine receptor (a7nAChR). It is conducting clinical trials only for certain indications under the anti-TNF platform. The Company is undertaking preclinical research and development activities for the SCA platform.

Number of employees: 4

Managers

Managers TitleAgeSince
Jonathan Rothbard FOU
 Founder 72 -
Jim Woody CEO
 Chief Executive Officer 81 -
Ozan Pamir DFI
 Director of Finance/CFO 33 30/09/18
Jason Assad IRC
 Investor Relations Contact - -

Members of the board

Members of the board TitleAgeSince
Lawrence Steinman FOU
 Founder 76 -
Jim Woody CEO
 Chief Executive Officer 81 -
Blair Jordan BRD
 Director/Board Member 55 02-27
Ozan Pamir DFI
 Director of Finance/CFO 33 30/09/18

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 1 0 0 96.65 %
Stock B 1 852,772 824,236 ( 96.65 %) 0
Stock C 0 1 0 0

Shareholders

NameEquities%Valuation
Citadel Securities GP LLC
2.856 %
24,356 2.856 % 56 749 $
Charles Schwab Investment Management, Inc.
2.153 %
18,364 2.153 % 42 788 $
Marc Feldmann
1.548 %
13,204 1.548 % 30 765 $
Virtu Financial LLC
0.4699 %
4,007 0.4699 % 9 336 $
Donald McGovern
0.3412 %
2,910 0.3412 % 6 780 $
Lawrence Steinman
0.2970 %
2,533 0.2970 % 5 902 $
Vanguard Group, Inc. (Subfiler)
0.2954 %
2,519 0.2954 % 5 869 $
Renaissance Technologies LLC
0.2675 %
2,281 0.2675 % 5 315 $
Jim Woody
0.2586 %
2,205 0.2586 % 5 138 $
HRT Financial LLC
0.2314 %
1,973 0.2314 % 4 597 $
NameEquities%Valuation
AQR Arbitrage LLC
-
223,232 - 1 786 $
MSD Partners LP
-
90,000 - 720 $
Two Sigma Securities LLC
-
39,201 - 314 $
Wolverine Asset Management LLC
-
3,098 - 25 $

Company contact information

180 Life Sciences Corp.

3000 El Camino Real Building 4

94306, Palo Alto

+

http://www.180lifesciences.com
address 180 Life Sciences Corp.(KBLM)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
180 LIFE SCIENCES CORP. Stock 180 Life Sciences Corp.
-55.63% 1.53M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. KBLM Stock
  4. Company 180 Life Sciences Corp.